WallStreetZenWallStreetZen

NASDAQ: ALNY
Alnylam Pharmaceuticals Inc Stock Ownership - Who owns Alnylam Pharmaceuticals?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Alnylam Pharmaceuticals Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Kevin Joseph FitzgeraldCSO EVP Head of Research2026-03-05153$326.24
$49.91kSell
Kevin Joseph FitzgeraldCSO EVP Head of Research2026-03-05148$324.60
$48.04kSell
Kevin Joseph FitzgeraldCSO EVP Head of Research2026-03-05233$323.25
$75.32kSell
Kevin Joseph FitzgeraldCSO EVP Head of Research2026-03-05124$321.81
$39.90kSell
Pushkal GargEVP Chief RD2026-03-05500$326.08
$163.04kSell
Pushkal GargEVP Chief RD2026-03-05654$322.33
$210.80kSell
Pushkal GargEVP Chief RD2026-03-05740$323.55
$239.43kSell
Pushkal GargEVP Chief RD2026-03-05510$324.59
$165.54kSell
Kevin Joseph FitzgeraldCSO EVP Head of Research2026-03-0479$321.82
$25.42kSell
Kevin Joseph FitzgeraldCSO EVP Head of Research2026-03-0459$320.81
$18.93kSell

1 of 45

ALNY insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ALNY insiders and whales buy or sell their stock.

ALNY Shareholders

What type of owners hold Alnylam Pharmaceuticals Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Capital World Investors12.29%16,301,772$5.35BInstitution
Fmr LLC11.99%15,902,149$5.22BInstitution
Ag Novartis11.16%14,800,620$4.86BInsider
Vanguard Group Inc10.22%13,553,932$4.45BInstitution
Sanofi7.96%10,554,134$3.46BInsider
Blackrock Inc7.84%10,400,874$3.41BInstitution
Capital Research Global Investors5.11%6,779,708$2.22BInstitution
Jpmorgan Chase Co3.56%4,719,999$1.55BInstitution
State Street Corp2.43%3,228,956$1.06BInstitution
Geode Capital Management LLC2.00%2,650,722$869.86MInstitution

1 of 3

ALNY vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ALNY82.36%17.64%Net SellingNet Selling
ARGX48.47%0.00%
ONC2.35%32.03%Net BuyingNet Buying
INSM85.00%15.00%Net SellingNet Selling
RPRX61.89%17.28%Net SellingNet Selling
View Top Biotech Stocks

Alnylam Pharmaceuticals Stock Ownership FAQ

Who owns Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ: ALNY) is owned by 97.82% institutional shareholders, 20.95% Alnylam Pharmaceuticals insiders, and 0.00% retail investors. Ag Novartis is the largest individual Alnylam Pharmaceuticals shareholder, owning 14.80M shares representing 11.16% of the company. Ag Novartis's Alnylam Pharmaceuticals shares are currently valued at $4.70B.

If you're new to stock investing, here's how to buy Alnylam Pharmaceuticals stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.